AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$SYRE

King-Jones Heidy sold $2.5M of SYRE

King-Jones Heidy (See Remarks) sold 28,399 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $87.35 ($86.40–$90.00, $2.48M total) across 5 trades over 2026-09-01 to 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · King-Jones Heidy
Published Sep 4, 2026, 1:34 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 1:36 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SYRE
Bearish
medium confidence
Mentioned
$SYRE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYREBearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which some investors view as a negative indicator.

02

Market read

Insider sell filings are monitored by traders for potential sentiment shifts; this filing may prompt short interest.

03

What to watch

Potential upcoming clinical data or financing events that could offset the sell pressure.

Relevance 5/10Novelty 4/10Timing: filed Sep 3, reported Sep 4

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$SYREBearishMedium confidence
Context

Officer Heidy King-Jones sold 28,399 shares for $2.48M via a 10b5-1 plan, reducing holdings to 2,845 shares.

Expected impact

Possible short-term downside pressure; traders may consider selling or reducing exposure.

Evidence & confidence

The sale represents a sizable stake reduction by an insider, but the amount is modest relative to market cap and typical for a 10b5-1 plan.

Market effects

Sector

May raise concerns for biotech sector investors tracking insider activity.

Regional

Limited to U.S. markets where SYRE trades.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale could be routine execution of a pre‑arranged plan, not a bearish signal.

Key entities

  • Company
    Spyre Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker SYRE.

  • Officer
    Heidy King-Jones

    Company officer who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SYRE insider trading history →

Related articles

SEP 17
$SYREMedAI 9/10

Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

Spyre Therapeutics (SYRE) reported that its anti-IL-23 antibody, SPY003, met primary endpoints in a Phase 2 trial, showing a 10.0-point reduction in Robart’s Histopathology Index score. This follows successful results for SPY001 and SPY002, completing proof-of-concept for all three molecules in its IBD portfolio. The company has $1.1 billion in cash, enough to fund operations into 2029. Part B of the SKYLINE trial, testing drug combinations, is still enrolling, with data expected in 2027. Spyre

insidermonkey.com2 min
SEP 11
$SYREMedAI 8/10

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

Spyre Therapeutics (SYRE) reported Phase 2 trial results for SPY003 in ulcerative colitis patients, showing a 10-point decline in tissue inflammation and 20% clinical remission. The study lacked a control arm, and further testing is needed. The company has $1.15B in cash and expects funding into 2029. Part B of the trial is enrolling, with results expected in 2027.

insidermonkey.com2 min
AUG 27
$SYREMedAI 8/10

Top Biotechnology Stock Pick from Guggenheim

Guggenheim maintains a buy rating on Spyre Therapeutics, citing positive Phase II SKYWAY-RA results for SPY072, despite discontinuing the rheumatoid arthritis program. The firm projects the stock to settle in the $90-95 range, with valuation based on the inflammatory bowel disease program. Other analysts have mixed views, with Wolfe Research downgrading and Mizuho raising its price target to $120.

investing.com2 min
AUG 26
$SYREHighAI 8/10

Why is Spyre Therapeutics stock sliding today?

Spyre Therapeutics (SYRE) stock fell 11.7% in pre-market trading after Phase 2 trial data for SPY072 in rheumatoid arthritis showed statistically significant but insufficient efficacy to advance as a monotherapy. Wedbush maintained an Outperform rating with a $130 target. The company plans further readouts in 2026 for other indications. The decline is attributed to the clinical news, not broader market trends.

investing.com2 min